Gregor, M

Janssen, J J W M; Löwenberg, B; Manz, M; Biemond, B J; Westerweel, P E; Klein, S K; Fehr, M; Sinnige, H A M; Efthymiou, A; Legdeur, M C J C; Pabst, T; Gregor, M; van der Poel, M W M; Deeren, D; Tick, L W; Jongen-Lavrencic, M; van Obbergh, F; Boersma, R S; de Weerdt, O; Chalandon, Y; ... (2022). Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia, 36(9), pp. 2189-2195. Nature Publishing Group 10.1038/s41375-022-01657-3

Gotta, V; Widmer, N; Decosterd, L A; Chalandon, Y; Heim, D; Gregor, M; Benz, R; Leoncini-Franscini, L; Baerlocher, Gabriela M.; Duchosal, M A; Csajka, C; Buclin, T (2014). Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer chemotherapy and pharmacology, 74(6), pp. 1307-1319. Springer 10.1007/s00280-014-2599-1

Taverna, C; Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C (2010). Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss medical weekly, 140, w13054. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2010.13054

Gratwohl, A; Heim, D; Bargetzi, M; Baerlocher, GM; Chalandon, Y; Duchosal, M; Gregor, M; Hess, U; Oppliger Leibundgut, E; Passweg, J; Schranz, U; Dirnhofer, S (2007). Behandlung der chronischen myeloischen Leukämie 2007. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS(7), pp. 934-940. Basel: EMH Editores Medicorum Helveticorum